ADVERTISEMENT
ADVERTISEMENT
This author has not written his bio yet.
But we are proud to say that Maren Kühr contributed 194 entries already.
The world of microbial product manufacturing is a complex landscape, driven by a diverse range of molecule formats and manufacturing processes. At the forefront of this specialty market is Boehringer Ingelheim Vienna, one global leader in biopharmaceutical development and manufacturing.
Swedish biotech startup AAX Biotech strengthens the management team with the appointment of Juan Astorga-Wells. He became new Senior Manager of Science & Development.
Organoid technology has emerged as one of the most groundbreaking and cutting-edge technologies in the biomedical field. It finds widespread applications in disease modeling, drug discovery and screening, companion diagnostics, cell therapy, regenerative medicine, and more.
Christine Lind will join Stockholm-based Bactiguard AB as new CEO at the Annual General Meeting in mid-May.
Stefanos Theoharis joins OneChain Immunotherapeutics (OCI) as new CEO. He follows Jorge Alemany, CEO since 2022, when the Spin-off from the Josep Carreras Leukemia Research Institute has started.
Dr Rob Scott, former Chief Medical Officer and Head of Development at AbbVie, joined Abionyx Pharma in January as new CMO and Head of Research and Development.
Uppsala-based ScandiNova Systems AB appoints Pernilla Enkler as the new Head of Sustainability, Quality and Communication – a newly established division.
With HAVEL LABS, a unique campus is being developed in Berlin-Spandau. Spanning over 20,000 m2, this space is designed for forward-thinking work environments. Modern industrial workplaces and logistics concepts, aligned with GMP (Good Manufacturing Practice) guidelines, can be effortlessly realised on the premises, as can laboratories ranging from safety level S1 to S3 in accordance with German Genetic Engineering Safety Regulations.
The Enlarged Board of Appeal (EBoA) of the European Patent Office will decide upon a question of high relevance for patents in the field biotechnology. The question to be decided concerns the interpretation of what has been “made available to the public”.
The city is investing in the future by establishing a modern campus and strengthening Mainz as a hub for life sciences. Space with convenient transport connections close to the city centre is available to found or relocate start-ups, companies and research facilities.